Découvrez nos professeurs et professeures!

Francesca Cicchetti

Professeure titulaire

Francesca Cicchetti
Centre thématique de recherche en neurosciences
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Neurosciences et santé mentale
Médecine régénératrice et moléculaire

Domaines et intérêts de recherche du (de la) professeur(e) :

Neurosciences, santé mentale et toxicomanies
  • Maladies neurodégénératives
  • Chorée de Huntington
  • Maladie de Parkinson

Projets de recherche

  • Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2020-04-01 au 2025-03-31
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-12-20 au 2024-12-19
  • Premier biomarqueur sanguin de la maladie de Parkinson : de la validation à la commercialisation - Fondation du CHU de Québec, Synucure Thérapeutique inc., Ministère de l'Économie et de l'Innovation - Projets de maturation technologique PSO – volet 2d, chercheur principal - 2022-09-14 au 2024-09-13
  • Redefining PD pathophysiology mechanisms in the context of teterogeneous substantia nigra neuron subtypes - Northwestern University - Target Advancement Program, chercheur principal - 2021-09-01 au 2024-08-31
  • Crosstalk at the blood-brain barrier: new insights into Parkinson's disease - National Parkinson Foundation, chercheur principal - 2022-06-30 au 2024-06-30
  • Untangling tau contribution to cognitive impairments in Huntington’s disease. - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2019-04-01 au 2024-03-31
  • Targeting the neurovascular unit to prevent disease dissemination and progression - Michael J. Fox Foundation for Parkinson's Research - Target Advancement Program, chercheur principal - 2021-01-01 au 2022-12-31
  • CRISPR-Cas9 nickase as a new approach to treat Huntington’s disease - Société Huntington du Canada, chercheur principal - 2019-07-01 au 2022-03-31
  • Interrogating induced neuronal cells from Huntington’s disease patients to better understand cognitive impairments - Huntington's Disease Society of America, chercheur principal - 2019-11-01 au 2021-11-01
  • Compréhension de la pathogénèse des maladies neurodégénératives et développement de stratégies thérapeutiques - Fonds de recherche du Québec - Santé - Chaires de recherche FRQS, chercheur principal - 2017-07-01 au 2021-06-30
  • Projet de recherche clinique sur la maladie de Parkinson (Cystamine) - Fondation du CHU de Québec, chercheur principal - 2019-04-01 au 2020-03-31

Publications

  • Passive immunization against phosphorylated tau improves features of Huntington's disease pathology, Melanie Alpaugh, Maria Masnata, Aurelie de Rus Jacquet, Eva Lepinay, Hélèna L. Denis, Martine Saint-Pierre, Peter Davies, Emmanuel Planel, Francesca Cicchetti, Molecular Therapy, 2022, 10.1016/j.ymthe.2022.01.020
  • Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins., , Cell reports, 2021, 10.1016/j.celrep.2021.109975
  • Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance., , Molecular psychiatry, 2021, 10.1038/s41380-021-01350-4
  • Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience., , Parkinsonism & related disorders, 2021, 10.1016/j.parkreldis.2021.08.018
  • Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders, Aurélie de Rus Jacquet, Hélèna L. Denis, Francesca Cicchetti, Melanie Alpaugh, Molecular Psychiatry, 2021, 10.1038/s41380-020-00999-7
  • Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders., , Molecular psychiatry, 2021, 10.1038/s41380-021-01055-8
  • Huntington's disease: lessons from prion disorders., , Journal of neurology, 2021, 10.1007/s00415-021-10418-8
  • Targeting Tau to Treat Clinical Features of Huntington's Disease., , Frontiers in neurology, 2020, 10.3389/fneur.2020.580732
  • Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases., , The Journal of experimental medicine, 2020, 10.1084/jem.20191430
  • Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.105042
  • Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology., , Molecular psychiatry, 2020, 10.1038/s41380-020-0787-4
  • Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104951
  • Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104943
  • Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104941
  • Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology., , Journal of neuroinflammation, 2020, 10.1186/s12974-020-01782-9
  • The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository., , Journal of Parkinson's disease, 2020, 10.3233/jpd-191775
  • Antibody-based therapies for Huntington's disease: current status and future directions., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104569
  • Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104530
  • A brief history of antibody-based therapy., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104504
  • A novel wireless brain stimulation device for long-term use in freely moving mice., , Scientific reports, 2019, 10.1038/s41598-019-42910-7
  • Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms., , Acta neuropathologica, 2019, 10.1007/s00401-019-01973-6
  • The troubling story of blood-driven dementias., , Molecular psychiatry, 2019, 10.1038/s41380-018-0225-z
  • The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice., , Brain research, 2019, 10.1016/j.brainres.2019.01.016
  • Platelet abnormalities in Huntington's disease., , Journal of neurology, neurosurgery, and psychiatry, 2018, 10.1136/jnnp-2018-318854
  • Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease., , Neurobiology of disease, 2018, 10.1016/j.nbd.2018.11.002
  • Outcome of cell suspension allografts in a patient with Huntington's disease., , Annals of neurology, 2018, 10.1002/ana.25354
  • Platelet-derived extracellular vesicles in Huntington's disease., , Journal of neurology, 2018, 10.1007/s00415-018-9022-5
  • Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders., , Journal of experimental neuroscience, 2018, 10.1177/1179069518772380
  • Are immunotherapies for Huntington's disease a realistic option?, , Molecular psychiatry, 2018, 10.1038/s41380-018-0021-9
  • Mutant huntingtin protein expression and blood-spinal cord barrier dysfunction in huntington disease., , Annals of neurology, 2017, 10.1002/ana.25107
  • Impact of DHA intake in a mouse model of synucleinopathy., , Experimental neurology, 2017, 10.1016/j.expneurol.2017.12.002
  • The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications., , Frontiers in neuroscience, 2017, 10.3389/fnins.2017.00647
  • Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease., , Brain : a journal of neurology, 2017, 10.1093/brain/awx255
  • The effects of cysteamine in a mouse model of levodopa-induced dyskinesias., , Neuroscience letters, 2017, 10.1016/j.neulet.2017.10.062
  • microRNA-132/212 deficiency enhances Aβ production and senile plaque deposition in Alzheimer's disease triple transgenic mice., , Scientific reports, 2016, 10.1038/srep30953
  • Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons., , Proceedings of the National Academy of Sciences of the United States of America, 2016, 10.1073/pnas.1520387113
  • Human-to-mouse prion-like propagation of mutant huntingtin protein., , Acta neuropathologica, 2016, 10.1007/s00401-016-1582-9
  • GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions., , Cell death & disease, 2016, 10.1038/cddis.2016.104
  • Is Huntington's disease a tauopathy?, , Brain : a journal of neurology, 2016, 10.1093/brain/aww021
  • Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?, , Acta neuropathologica, 2015, 10.1007/s00401-015-1518-9
  • Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system., , The Journal of nutritional biochemistry, 2015, 10.1016/j.jnutbio.2015.11.014
  • Targeting cerebrovascular impairments in Huntington's disease: a novel treatment perspective., , Neurodegenerative disease management, 2015, 10.2217/nmt.15.41
  • Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease., , Neurobiology of disease, 2015, 10.1016/j.nbd.2015.07.012
  • The role of tau in the pathological process and clinical expression of Huntington's disease., , Brain : a journal of neurology, 2015, 10.1093/brain/awv107
  • Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology., , Annals of neurology, 2015, 10.1002/ana.24406
  • A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice., , The Journal of physiology, 2015, 10.1113/jphysiol.2014.287243
  • The morphological and molecular changes of brain cells exposed to direct current electric field stimulation., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu090
  • Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu103
  • Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu047
  • Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling., , Cell reports, 2014, 10.1016/j.celrep.2014.10.008
  • Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease., , Human molecular genetics, 2014, 10.1093/hmg/ddu456
  • Neurodegenerative disorders: the Glia way forward., , Frontiers in pharmacology, 2014, 10.3389/fphar.2014.00157
  • The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?, , Frontiers in pharmacology, 2014, 10.3389/fphar.2014.00139
  • Mutant huntingtin is present in neuronal grafts in Huntington disease patients., , Annals of neurology, 2014, 10.1002/ana.24174
  • The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence., , Neuropathology and applied neurobiology, 2014, 10.1111/nan.12104
  • The different effects of LPS and poly I:C prenatal immune challenges on the behavior, development and inflammatory responses in pregnant mice and their offspring., , Brain, behavior, and immunity, 2013, 10.1016/j.bbi.2013.12.016
  • Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease., , Cell transplantation, 2013, 10.3727/096368913x668636
  • Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability., , Brain : a journal of neurology, 2013, 10.1093/brain/aws359
  • Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease., , Journal of neuroinflammation, 2012, 10.1186/1742-2094-9-234
  • Inflammation and neurodegeneration: the story 'retolled'., , Trends in pharmacological sciences, 2012, 10.1016/j.tips.2012.07.002
  • An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity., , Cell death & disease, 2012, 10.1038/cddis.2012.121
  • Current understanding of the glial response to disorders of the aging CNS., , Frontiers in pharmacology, 2012, 10.3389/fphar.2012.00095
  • MyD88 deficiency results in both cognitive and motor impairments in mice., , Brain, behavior, and immunity, 2012, 10.1016/j.bbi.2012.02.007
  • Neuroanatomy and neuroscience at a glance, , Wiley-Blackwell, 2012
  • The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration., , Journal of neuroinflammation, 2011, 10.1186/1742-2094-8-137
  • High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice., , Neurobiology of disease, 2011, 10.1016/j.nbd.2011.09.009
  • The role of immunity in Huntington's disease., , Molecular psychiatry, 2011, 10.1038/mp.2011.28
  • Impact of ω-3 fatty acids in Parkinson's disease., , Ageing research reviews, 2011, 10.1016/j.arr.2011.03.001
  • The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity., , Brain, behavior, and immunity, 2011, 10.1016/j.bbi.2011.02.017
  • Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions., , Glia, 2011, 10.1002/glia.21086
  • Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications., , Brain : a journal of neurology, 2011, 10.1093/brain/awq328
  • Pesticides and Parkinson’s Disease, , Pesticides - The Impacts of Pesticides Exposure, 2011
  • Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease., , Journal of lipid research, 2010, 10.1194/jlr.m011692
  • Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases., , Progress in neuro-psychopharmacology & biological psychiatry, 2010, 10.1016/j.pnpbp.2010.11.023
  • Technical factors that influence neural transplant safety in Huntington's disease., , Experimental neurology, 2010, 10.1016/j.expneurol.2010.08.031
  • Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases., , Journal of neurochemistry, 2010, 10.1111/j.1471-4159.2010.06874.x
  • Viability of the rotenone model in question, , Trends in Pharmacological Sciences, 2010, 10.1016/j.tips.2009.12.008
  • Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor., , Progress in neuro-psychopharmacology & biological psychiatry, 2009, 10.1016/j.pnpbp.2009.11.005
  • Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?, , Trends in pharmacological sciences, 2009, 10.1016/j.tips.2009.06.005
  • Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model., , Progress in neuro-psychopharmacology & biological psychiatry, 2009, 10.1016/j.pnpbp.2009.07.018
  • Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration., , Proceedings of the National Academy of Sciences of the United States of America, 2009, 10.1073/pnas.0904239106
  • Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions., , Journal of neurochemistry, 2009, 10.1111/j.1471-4159.2009.06072.x
  • Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease., , FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, 10.1096/fj.07-9677com
  • Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007, 10.2967/jnumed.106.037796
  • Dual-modality in vivo monitoring of subventricular zone stem cell migration and metabolism., , Contrast media & molecular imaging, 2007, 10.1002/cmmi.138
  • Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats., , Journal of neurochemistry, 2006, 10.1111/j.1471-4159.2006.03923.x
  • Neuroprotective effects of cystamine in aged parkinsonian mice., , Neurobiology of aging, 2006, 10.1016/j.neurobiolaging.2005.04.004
  • Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats., , Neurobiology of disease, 2005, 10.1016/j.nbd.2005.03.018
  • Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease., , Journal of the neurological sciences, 2005, 10.1016/j.jns.2004.12.011
  • 3-Nitropropionic acid-induced neurotoxicity--assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy., , Journal of neurochemistry, 2004, 10.1111/j.1471-4159.2004.02408.x
  • Rotenone induces non-specific central nervous system and systemic toxicity., , FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, 10.1096/fj.03-0677fje
  • Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress., , Neurotoxicity research, 2004, 10.1007/bf03033216
  • Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model., , NeuroImage, 2003, 10.1016/s1053-8119(03)00348-3
  • Immune parameters relevant to neural xenograft survival in the primate brain., , Xenotransplantation, 2003, 10.1034/j.1399-3089.2003.01130.x
  • Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain., , Experimental neurology, 2002, 10.1006/exnr.2002.8007
  • Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging., , The European journal of neuroscience, 2002, 10.1046/j.1460-9568.2002.01938.x
  • Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat., , Experimental neurology, 2001, 10.1006/exnr.2001.7823
  • Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells., , Parkinsonism & related disorders, 2001, 10.1016/s1353-8020(00)00059-6
  • Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum., , Neuroscience, 2001, 10.1016/s0306-4522(01)00098-7
  • Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology., , Proceedings of the National Academy of Sciences of the United States of America, 2000, 10.1073/pnas.97.25.13877
  • Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease., , Brain research. Brain research reviews, 2000, 10.1016/s0165-0173(00)00039-4
  • Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene., , Brain research, 1999, 10.1016/s0006-8993(98)01312-2
  • Differential expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits by calretinin-immunoreactive neurons in the human striatum., , Neuroscience, 1999, 10.1016/s0306-4522(99)00110-4
  • Chemical phenotype of calretinin interneurons in the human striatum., , Synapse (New York, N.Y.), 1998, 10.1002/(sici)1098-2396(199811)30:3<284::aid-syn6>3.0.co;2-7
  • The current model of basal ganglia organization under scrutiny., , Movement disorders : official journal of the Movement Disorder Society, 1998, 10.1002/mds.870130202
  • Calretinin gene expression in the human thalamus., , Brain research. Molecular brain research, 1998, 10.1016/s0169-328x(97)00314-8
  • [Anatomy and physiopathology of the basal ganglia], , Neuro-Chirurgie, 1997
  • Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons., , Movement disorders : official journal of the Movement Disorder Society, 1996, 10.1002/mds.870110605
  • Calcium-binding proteins in primate basal ganglia., , Neuroscience research, 1996, 10.1016/0168-0102(96)01065-6
  • Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease., , Brain research, 1996, 10.1016/0006-8993(96)00307-1
  • Calretinin-immunoreactive neurons in the human striatum., , Brain research, 1995, 10.1016/0006-8993(95)00124-9
  • Striatal neurones displaying substance P (NK1) receptor immunoreactivity in human and non-human primates., , Neuroreport, 1995, 10.1097/00001756-199503270-00004

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Karla Paulina Sanchez Cortes - Maitrîse avec mémoire - En cours
  • Leila Nasrallah - Doctorat - En cours
  • Christine Trabolsi - Doctorat - En cours
  • Ghassen Bougamra - Maitrîse avec mémoire - En cours
  • Eva Lepinay - Maitrîse avec mémoire - En cours
  • Thyago Cardim Pires - Post-doctorat - En cours
  • Julie Cazelais - Maitrîse avec mémoire - En cours
  • Marilyn Dubois - Doctorat - En cours
  • Mohamed Lala bouali - Doctorat - En cours
  • Thomson Joseph - Post-doctorat - En cours
  • Karl-Indel Gué - Maitrîse avec mémoire - 2012/01
  • Giulia Cisbani - Doctorat - 2014/09
  • Simon Pelletier - Maitrîse avec mémoire - 2015/01
  • Marie Rieux - Maitrîse avec mémoire - 2017/01
  • Katherine Coulombe - Maitrîse avec mémoire - 2017/09
  • Jérôme Lamontagne-Proulx - Maitrîse avec mémoire - 2018/01
  • Alexander Maxan - Maitrîse avec mémoire - 2019/01
  • Florian Lauruol - Maitrîse avec mémoire - 2019/05
  • Maria Masnata - Doctorat - 2020/09
  • Héléna Denis - Maitrîse avec mémoire - 2021/01
  • Giacomo Sciacca - Doctorat - 2021/09

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.